title: What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
abstract: OBJECTIVE
  Short prostate specific antigen doubling time following recurrence after radical prostatectomy portends a poor prognosis in men with prostate cancer. We determined which demographic and clinicopathological variables were predictive of a short prostate specific antigen doubling time in a cohort of men with clinically localized prostate cancer treated with radical prostatectomy.
  
  
  METHODS
  Data on 856 men from the Shared Equal Access Regional Cancer Hospital database who underwent radical prostatectomy for node negative prostate cancer between 1988 and 2003 were included in the analysis. We used logistic regression analysis to determine the independent factors associated with a short prostate specific antigen doubling time of less than 9 months vs a longer doubling time of 9 months or greater, or no recurrence. The variables analyzed were patient age, race, logarithmically transformed preoperative prostate specific antigen, body mass index, year of surgery, pathological Gleason sum, extraprostatic extension, surgical margin status and seminal vesicle invasion.
  
  
  RESULTS
  On multivariate analysis higher preoperative prostate specific antigen (OR 2.20, 95% CI 1.52-3.19, p <0.001), pathological Gleason sum 8-10 (OR 4.70, 95% CI 2.11-10.43, p <0.001) and 7 (OR 2.11, 95% CI 1.09-4.08, p = 0.026), tumors with extraprostatic extension and/or positive surgical margins (OR 2.08, 95% CI 1.48-3.91, p = 0.023), and seminal vesicle invasion (OR 3.26, 95% CI 1.48-7.21, p = 0.003) were independent predictors of a short prostate specific antigen doubling time. Based on these risk factors we developed a table to estimate the risk of recurrence with a prostate specific antigen doubling time of less than 9 months.
  
  
  CONCLUSIONS
  The factors that are invariably used to predict overall biochemical recurrence following radical prostatectomy, including high prostate specific antigen, high grade and adverse pathological findings, also predict aggressive recurrence.
authors.affiliation: Division of Urologic Surgery and Duke Prostate Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: Anna E
authors.initials: AE
authors.lastname: Teeter
authors.forename: Lionel L
authors.initials: LL
authors.lastname: Bañez
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Presti
authors.forename: William J
authors.initials: WJ
authors.lastname: Aronson
authors.forename: Martha K
authors.initials: MK
authors.lastname: Terris
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kane
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Amling
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Freedland
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001707:Biopsy, Needle; D016001:Confidence Intervals; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D016017:Odds Ratio; D011182:Postoperative Care / Q000379:methods; D011237:Predictive Value of Tests; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012042:Registries; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
references.citation: J Urol. 2001 Jan;165(1):119-25
references.pmid: 11125379
references.citation: J Urol. 2002 Jan;167(1):103-11
references.pmid: 11743285
references.citation: Urology. 2002 Oct;60(4):670-4
references.pmid: 12385931
references.citation: J Urol. 2003 Jun;169(6):2142-6
references.pmid: 12771736
references.citation: J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83
references.pmid: 13130113
references.citation: Cancer Chemother Rep. 1966 Mar;50(3):125-8
references.pmid: 5948714
references.citation: JAMA. 1998 Sep 16;280(11):969-74
references.pmid: 9749478
references.citation: JAMA. 1999 May 5;281(17):1591-7
references.pmid: 10235151
references.citation: J Clin Oncol. 1999 May;17(5):1499-507
references.pmid: 10334537
references.citation: Urology. 2005 Mar;65(3):528-32
references.pmid: 15780370
references.citation: JAMA. 2005 Jul 27;294(4):433-9
references.pmid: 16046649
references.citation: J Clin Oncol. 2005 Aug 1;23(22):4975-9
references.pmid: 16051949
references.citation: Eur Urol. 2005 Oct;48(4):541-5
references.pmid: 16139417
references.citation: Urol Int. 2006;77(2):130-4
references.pmid: 16888417
references.citation: J Urol. 2006 Oct;176(4 Pt 1):1404-8
references.pmid: 16952644
references.citation: JAMA. 2006 Nov 15;296(19):2329-35
references.pmid: 17105795
references.citation: Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71
references.pmid: 16979837
references.citation: Urol Oncol. 2007 Mar-Apr;25(2):110-4
references.pmid: 17349524
references.citation: J Clin Oncol. 2007 May 1;25(13):1765-71
references.pmid: 17470867
references.citation: Urology. 2007 Jun;69(6):1095-101
references.pmid: 17572194